News
The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...
A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...
Clinical Trials Arena on MSN17h
Novartis culls ianalumab in HS after Phase IIb trial failureAbbVie’s flagship Humira (adalimumab) is also approved in HS and was the first biologic to be approved in the indication in ...
Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...
In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...
Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year ...
Novartis appoints Mukul Mehta as CFO, as Harry Kirsch retires after 22 years with the company: Basel Friday, July 18, 2025, ...
Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...
Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...
Novartis made one of the biggest investments in Cannes among pharma companies, sending approximately 20 people from the ...
Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback